107 related articles for article (PubMed ID: 20539208)
21. Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).
Galetta D; Giotta F; Rosati G; Gebbia V; Manzione L; Di Bisceglie M; Borsellino N; Colucci G
Anticancer Res; 2005; 25(6C):4445-9. PubMed ID: 16334124
[TBL] [Abstract][Full Text] [Related]
22. Combined radiotherapy and CMF-B cytotoxic regimen in stage III-IV head and neck squamous cell carcinoma.
Tatarek R; Merlano M; Rosso R; Corvò L
Chemioterapia; 1984 Oct; 3(5):330-2. PubMed ID: 6085287
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of squamous cell carcinoma of the head and neck with multi-drug chemotherapy and radiotherapy].
Nishio M; Kagami Y; Narimatsu N; Asano K; Sanbe S; Somekawa Y
Gan To Kagaku Ryoho; 1989 Sep; 16(9):3111-8. PubMed ID: 2476971
[TBL] [Abstract][Full Text] [Related]
24. [Immunotherapy for head and neck squamous cell carcinoma].
Bron L; Romero P
Rev Med Suisse; 2006 Oct; 2(81):2216-9. PubMed ID: 17076151
[TBL] [Abstract][Full Text] [Related]
25. Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules.
Moreno-Jiménez M; Valero J; López-Picazo JM; Arbea L; Aristu J; Cambeiro M; Alcalde J; Martínez-Monge R
Am J Clin Oncol; 2010 Apr; 33(2):137-43. PubMed ID: 19786847
[TBL] [Abstract][Full Text] [Related]
26. Chemo-immunotherapy in advanced head and neck cancer.
Recchia F; Sica G; De Filippis S; Rosselli M; Pompili P; Saggio G; Rea S
Anticancer Res; 1999; 19(1B):773-7. PubMed ID: 10216492
[TBL] [Abstract][Full Text] [Related]
27. [Clinical efficacy of combined treatment in a late-stage malignant tumor of the head and neck].
Jin BL
Zhonghua Kou Qiang Yi Xue Za Zhi; 1987 May; 22(3):162-3. PubMed ID: 3478183
[No Abstract] [Full Text] [Related]
28. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Lippman SM; Ginsberg L; Diaz E; Papadimitrakopoulou V; Feng L; Francisco M; Garden A; Kies MS; Myers J; Clayman G; Hong WK
Cancer; 2002 Jul; 95(2):322-30. PubMed ID: 12124833
[TBL] [Abstract][Full Text] [Related]
29. [Adjuvant chemotherapy in advanced squamous cell carcinoma of the head and neck].
Zhou T; Zeng Z
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1995; 30(3):171-3. PubMed ID: 8579878
[TBL] [Abstract][Full Text] [Related]
30. [Combination therapy with S-1 and CDDP for head and neck cancer].
Fujii M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():150-4. PubMed ID: 16897992
[TBL] [Abstract][Full Text] [Related]
31. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
[TBL] [Abstract][Full Text] [Related]
32. Concomitant administration of two standard regimens of chemotherapy and radiotherapy in advanced squamous carcinoma of the head and neck: a feasibility study.
Benasso M; Corvò R; Numico G; Cavallari M; Blengio F; Sanguineti G; Rosso M; Merlano M
Anticancer Res; 1995; 15(6B):2651-4. PubMed ID: 8669841
[TBL] [Abstract][Full Text] [Related]
33. CCND1 amplification predicts sensitivity to chemotherapy and chemoradiotherapy in head and neck squamous cell carcinoma.
Ishiguro R; Fujii M; Yamashita T; Tashiro M; Tomita T; Ogawa K; Kameyama K
Anticancer Res; 2003; 23(6D):5213-20. PubMed ID: 14981992
[TBL] [Abstract][Full Text] [Related]
34. A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer.
Verastegui E; Barrera JL; Zinser J; Del Rio R; Meneses A; De La Garza J; Hadden JW
Int J Immunopharmacol; 1997; 19(11-12):619-27. PubMed ID: 9669202
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for head and neck squamous cell carcinoma.
Li Q; Prince ME; Moyer JS
Oral Oncol; 2015 Apr; 51(4):299-304. PubMed ID: 25624094
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen.
Liu S; Bellile E; Nguyen A; Zarins K; D'Silva N; Rozek L; Wolf GT; Sartor MA;
Oral Oncol; 2021 Dec; 123():105587. PubMed ID: 34717154
[TBL] [Abstract][Full Text] [Related]
37. Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial.
Wolf GT; Liu S; Bellile E; Sartor M; Rozek L; Thomas D; Nguyen A; Zarins K; McHugh JB;
Oral Oncol; 2020 Dec; 111():104928. PubMed ID: 32738599
[TBL] [Abstract][Full Text] [Related]
38. A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma.
Whiteside TL; Butterfield LH; Naylor PH; Egan JE; Hadden JW; Baltzer L; Wolf GT; Berinstein NL
Cancer Immunol Immunother; 2012 Jun; 61(6):783-8. PubMed ID: 22109700
[TBL] [Abstract][Full Text] [Related]
39. Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC.
Jiang P; Zhang Y; J Archibald S; Wang H
Int Immunopharmacol; 2015 Sep; 28(1):208-14. PubMed ID: 26066298
[TBL] [Abstract][Full Text] [Related]
40. IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers.
Wolf GT; Moyer JS; Kaplan MJ; Newman JG; Egan JE; Berinstein NL; Whiteside TL
Onco Targets Ther; 2018; 11():3731-3746. PubMed ID: 29988729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
